HDL-inflammatory index correlates with poor outcome in hemodialysis patients

Kidney International

Volumn 72, Issue 9, 2007, Pages 1149-1156

  Kalantar Zadeh, K ^a   Kopple, J D ^a   Kamranpour, N ^b   Fogelman, A M ^b   Navab, M ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dialysis; HDL; Hemodialysis; Inflammation; LDL

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY FAT; CHRONIC KIDNEY DISEASE; CORRELATION FUNCTION; DEATH; FAT CONTENT; FEMALE; FLUORESCENCE; HAZARD RATIO; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEAR INFRARED SPECTROSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SHORT FORM 36;

BIOLOGICAL MARKERS; BODY COMPOSITION; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROGNOSIS; QUALITY OF LIFE; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 35349021522     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002491     Document Type: Article

References (52)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System: Excerpts from the USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Am J Kidney Dis 2006; 47(Suppl 1): 1-286.
3. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
4. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
5. Kalantar-Zadeh K, Ikizler TA, Block G et al. Malnutrition- inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881.
6. McClellan WM, Chertow GM. Beyond framingham: cardiovascular risk profiling in ESRD. J Am Soc Nephrol 2005; 16: 1539-1541.
7. Navab M, Ananthramaiah GM, Reddy ST et al. Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1007.
8. Huang YH, Ronnelid J, Frostegard J. Oxidized LDL induces enhanced antibody formation and MCH class II-dependent INF-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol 1995; 15: 1577-1583.
9. Jovinge S, Ares MP, Kallin B et al. Human monocytes/macrophages release TNF alpha in response to oxidized LDL. Arterioscler Thromb Vasc Biol 1996; 1996: 1573-1579.
10. Navab M, Berliner JA, Watson AD et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
11. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
12. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353: 9-11.
13. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005; 15: 212-219.
14. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase levels predict mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48: 59-68.
15. Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-488.
16. Navab M, Ananthramaiah GM, Reddy ST et al. The double jeopardy of HDL. Ann Med 2005; 37: 173-178.
17. Navab M, Hama SY, Ready ST et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002; 13: 363-372.
18. Ansell BJ, Navab M, Hama S et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
19. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880-1889.
20. Kopple JD, Greene T, Chumlea WC et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 2000; 57: 1688-1703.
21. Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int 2006; 10: 315-325.
22. Kilpatrick RD, McAllister CJ, Kovesdy CP et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303.
23. Morena M, Cristol JP, Dantoine T et al. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 389-395.
24. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893.
25. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
26. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
27. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
28. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003; 13: 144-148.
29. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif 2001; 19: 143-151.
30. Kaysen GA, Chertow GM, Adhikarla R et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60: 333-340.
31. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41: 925-932.
32. Kalantar-Zadeh K, Block G, Horwich T et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439-1444.
33. Beddhu S, Ramkumar N, Samore MH. The paradox of the BMI paradox in dialysis patients: associations of adiposity with inflammation. Am J Clin Nutr 2005; 82: 909-910.
34. Kalantar-Zadeh K, Abbott KC, Salahudeen AK et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-554.
35. Beddhu S, Pappas LM, Ramkumar N et al. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14: 2366-2372.
36. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-2549.
37. Kalantar-Zadeh K, Block G, Humphreys MH et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453.
38. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
39. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 337-342.
40. Beddhu S, Bruns FJ, Saul M et al. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-613.
41. Kalantar-Zadeh K, Kopple JD, Block G et al. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001; 12: 2797-2806.
42. Diaz-Buxo JA, Lowrie EG, Lew NL et al. Quality-of-life evaluation using Short Form 36: comparison in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2000; 35: 293-300.
43. Nelson EE, Hong CD, Pesce AL et al. Anthropometric norms for the dialysis population. Am J Kidney Dis 1990; 16: 32-37.
44. Williams AJ, McArley A. Body composition, treatment time, and outcome in hemodialysis patients. J Ren Nutr 1999; 9: 157-162.
45. Kalantar-Zadeh K, Dunne E, Nixon K et al. Near infra-red interactance for nutritional assessment of dialysis patients. Nephrol Dial Transplant 1999; 14: 169-175.
46. Kalantar-Zadeh K, Kuwae N, Wu DY et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202-210.
47. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
48. Erbagci AB, Tarakcioglu M, Aksoy M et al. Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol 2002; 57: 197-204.
49. Pecoits-Filho R, Barany P, Lindholm B et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-1688.
50. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39: 274-282.
51. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of host response. Ann Rev Immunol 1989; 7: 625-655.
52. Navab M, Hama SY, Hough GP et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42: 1308-1317.